CPRX - Catalyst Pharmaceuticals, Inc.
| Previous Close | 6.13 |
| Open | 6.63 |
| Bid | 6.17 x 2200 |
| Ask | 6.27 x 28000 |
| Day's Range | 6.01 - 6.82 |
| 52 Week Range | 1.85 - 7.67 |
| Volume | 7,791,126 |
| Avg. Volume | 1,667,855 |
| Market Cap | 639.189M |
| Beta (3Y Monthly) | 2.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.12 |
| Earnings Date | Aug 10, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.33 |
- Zacks
Catalyst Pharmaceutical (CPRX) is a Great Momentum Stock: Should You Buy?
Does Catalyst Pharmaceutical (CPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks
Implied Volatility Surging for Catalyst (CPRX) Stock Options
Investors need to pay close attention to Catalyst (CPRX) stock based on the movements in the options market lately.
- Benzinga
The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 11) Ardelyx Inc (NASDAQ: ARDX ) Avedro Inc (NASDAQ: AVDR ...
- GlobeNewswire
Catalyst Pharmaceuticals, Inc. Determines Not to Proceed with Previously Announced Public Offering of Common Stock
Catalyst Pharmaceuticals, Inc. (CPRX) today announced that it will not conclude the offering of shares of its common stock announced on Wednesday, September 11, 2019. The Company believes that the culmination of an offering at the current market price of the common stock is not in the best interest of the Company and its stockholders. Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis (MuSK-MG), congenital myasthenic syndromes (CMS), and spinal muscular atrophy (SMA) Type 3.
- GlobeNewswire
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Catalyst Pharmaceuticals, Inc. (CPRX) announced today that it has commenced an underwritten public offering of 8.0 million shares of its common stock. Catalyst also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All of the shares in the offering are being sold by Catalyst.
- Zacks
Investors Can Find Big Returns with this First Profit Screen
Investors Can Find Big Returns with this First Profit Screen
- Thomson Reuters StreetEvents
Edited Transcript of CPRX earnings conference call or presentation 8-Aug-19 12:30pm GMT
Q2 2019 Catalyst Pharmaceuticals Inc Earnings Call
- Zacks
Why Is Catalyst (CPRX) Up 23% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Catalyst Pharmaceuticals (CPRX) Looks Good: Stock Adds 6% in Session
Catalyst Pharmaceuticals (CPRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- GlobeNewswire
Catalyst Pharmaceuticals to Participate in the 14th Annual Citi Biotech Conference on September 4th, 2019
CORAL GABLES, Fla., Aug. 28, 2019 -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative.
- Zacks
Here's How to Find Top-Ranked Stocks Under $10 to Buy
Here's How to Find Top-Ranked Stocks Under $10 to Buy
- Zacks
Top Ranked Momentum Stocks to Buy for August 19th
Top Ranked Momentum Stocks to Buy for August 19th
- Zacks
Will Catalyst Pharmaceuticals Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor Catalyst Pharmaceuticals.
- Simply Wall St.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): The Best Of Both Worlds
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on...
- Motley Fool
Why Catalyst Pharmaceuticals Stock Broke Down Today
Catalyst's shares took a sizable hit this morning.
- Zacks
Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates
Catalyst (CPRX) surpasses earnings and sales estimates in the second quarter of 2019.
- Zacks
Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of 233.33% and 50.18%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Catalyst Pharmaceuticals Announces Second Quarter 2019 Financial Results and Provides Corporate Update
Firdapse® Launch Momentum Continues with Second Quarter Net Revenues of $28.8 Million 409 Adult LEMS Patients Active on Firdapse as of June 30, 2019 Company to Host Quarterly.
- Motley Fool
2 Small-Cap Stocks That Could Make You Rich
The small-cap healthcare stocks Catalyst Pharmaceuticals and MedMen Enterprises have enormous upside potential.
- GlobeNewswire
Catalyst Pharmaceuticals Announces Its Support of Spinal Muscular Atrophy Awareness Month
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced its support of Spinal Muscular Atrophy (SMA) Awareness Month. Taking place in August, SMA Awareness Month involves activities worldwide to spotlight the work the SMA community does year-round to raise awareness of the debilitating and potentially deadly disease. “We are proud to be part of the global movement to raise awareness of SMA and recognize the importance of developing new evidence-based medicines required to improve the lives of patients, families and caregivers afflicted with SMA,” said Patrick J. McEnany, Chairman and CEO of Catalyst.
- Motley Fool
2 Top Stocks to Buy in August
Adverum Biotechnologies and Catalyst Pharmaceuticals could both post sizable gains next month.
- GlobeNewswire
Catalyst Pharmaceuticals to Hold Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 8th, 2019
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release second quarter 2019 financial result after market close on Wednesday, August 7, 2019. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. ET on Thursday, August 8th, 2019 to discuss the financial results and to provide a corporate update. Investors who wish to participate in the conference call may do so by dialing (877) 407-8912 for domestic and Canadian callers or (201) 689-8059 for international callers.
- Simply Wall St.
Do Directors Own Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares?
If you want to know who really controls Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), then you'll have to look at the...
- Zacks
Catalyst Pharma Focuses on Firdapse Launch & Label Expansion
Catalyst Pharmaceuticals (CPRX) intends to launch Firdapse and expand the label of the same.
